Ampio calls off a $30M IPO for its men’s health offshoot

Damian Garde

Pharmaceuticals has postponed a plot to spin out one of its subsidiaries through an IPO, citing unfavorable market conditions.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS